Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 674 clinical trials
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy …

  • 0 views
  • 09 May, 2022
  • 2 locations
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of Donafenib combined with KN046 in subjects with Advanced Gastrointestinal Tumors.

  • 0 views
  • 06 Apr, 2021
  • 1 location
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

This is an open-label phase 1 study with an escalation part and an expansion part.

  • 0 views
  • 11 Jul, 2022
  • 1 location
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B (ADAPT)

Multicenter, Prospective Open-label Single Arm Trial Chronic hepatitis B male and female adults on antiviral treatment for hepatitis B, without cirrhosis who are currently HBV DNA (-) and HBeAg (-) To evaluate the safety and efficacy of stopping long-term antiviral therapy in chronic hepatitis B patients without cirrhosis who are …

  • 0 views
  • 27 May, 2022
  • 9 locations
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were advanced intrahepatic cholangiocarcinoma with no chance for primary surgery.

  • 2 views
  • 24 Jan, 2021
  • 1 location
GD2/CD70 Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70 bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor. Another goal of the study is to learn more about the function of the GD2/CD70 bi-specific CAR-T cells and their persistency in patients.

  • 0 views
  • 10 Jul, 2022
  • 1 location
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic Hepatitis D Virusinfection. Objectives: To evaluate the safety and tolerability of once daily dosing of lonafarnib …

  • 0 views
  • 22 Mar, 2022
  • 1 location
A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma

the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for locoregional therapy. In this study, CS1003

liver cancer
cancer
measurable disease
hepatitis
lenvatinib
  • 58 views
  • 24 Feb, 2022
  • 6 locations
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High

  • 0 views
  • 27 Aug, 2021
  • 2 locations
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3)

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive

nivolumab
TACE
platelet count
renal function
neutrophil count
  • 19 views
  • 27 Feb, 2022
  • 1 location